141 related articles for article (PubMed ID: 36831011)
1. Targeting Mitochondrial IDH2 Enhances Antitumor Activity of Cisplatin in Lung Cancer via ROS-Mediated Mechanism.
Li H; Li JJ; Lu W; Yang J; Xia Y; Huang P
Biomedicines; 2023 Feb; 11(2):. PubMed ID: 36831011
[TBL] [Abstract][Full Text] [Related]
2. IDH2, a novel target of OGT, facilitates glucose uptake and cellular bioenergy production via NF-κB signaling to promote colorectal cancer progression.
He X; Wu N; Li R; Zhang H; Zhao Y; Nie Y; Wu J
Cell Oncol (Dordr); 2023 Feb; 46(1):145-164. PubMed ID: 36401762
[TBL] [Abstract][Full Text] [Related]
3. Gallic acid induces apoptosis and enhances the anticancer effects of cisplatin in human small cell lung cancer H446 cell line via the ROS-dependent mitochondrial apoptotic pathway.
Wang R; Ma L; Weng D; Yao J; Liu X; Jin F
Oncol Rep; 2016 May; 35(5):3075-83. PubMed ID: 26987028
[TBL] [Abstract][Full Text] [Related]
4. Reductive TCA cycle catalyzed by wild-type IDH2 promotes acute myeloid leukemia and is a metabolic vulnerability for potential targeted therapy.
Zeng P; Lu W; Tian J; Qiao S; Li J; Glorieux C; Wen S; Zhang H; Li Y; Huang P
J Hematol Oncol; 2022 Mar; 15(1):30. PubMed ID: 35313945
[TBL] [Abstract][Full Text] [Related]
5. Wild-type IDH2 protects nuclear DNA from oxidative damage and is a potential therapeutic target in colorectal cancer.
Qiao S; Lu W; Glorieux C; Li J; Zeng P; Meng N; Zhang H; Wen S; Huang P
Oncogene; 2021 Sep; 40(39):5880-5892. PubMed ID: 34349242
[TBL] [Abstract][Full Text] [Related]
6. Wild-type IDH2 contributes to Epstein-Barr virus-dependent metabolic alterations and tumorigenesis.
Shi F; He Y; Li J; Tang M; Li Y; Xie L; Zhao L; Hu J; Luo X; Zhou M; Liu N; Fan J; Zhou J; Gao Q; Qiu S; Wu W; Zhang X; Jia W; Bode AM; Cao Y
Mol Metab; 2020 Jun; 36():100966. PubMed ID: 32224436
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of isocitrate dehydrogenase mutant proteins renders glioma cells more sensitive to radiation.
Li S; Chou AP; Chen W; Chen R; Deng Y; Phillips HS; Selfridge J; Zurayk M; Lou JJ; Everson RG; Wu KC; Faull KF; Cloughesy T; Liau LM; Lai A
Neuro Oncol; 2013 Jan; 15(1):57-68. PubMed ID: 23115158
[TBL] [Abstract][Full Text] [Related]
8. Mitochondrial NADP
Kong MJ; Han SJ; Kim JI; Park JW; Park KM
Cell Death Dis; 2018 May; 9(5):488. PubMed ID: 29695796
[TBL] [Abstract][Full Text] [Related]
9. High levels of EGFR prevent sulforaphane-induced reactive oxygen species-mediated apoptosis in non-small-cell lung cancer cells.
Wang TH; Chen CC; Huang KY; Shih YM; Chen CY
Phytomedicine; 2019 Nov; 64():152926. PubMed ID: 31454652
[TBL] [Abstract][Full Text] [Related]
10. Wild-type IDH2 promotes the Warburg effect and tumor growth through HIF1α in lung cancer.
Li J; He Y; Tan Z; Lu J; Li L; Song X; Shi F; Xie L; You S; Luo X; Li N; Li Y; Liu X; Tang M; Weng X; Yi W; Fan J; Zhou J; Qiang G; Qiu S; Wu W; Bode AM; Cao Y
Theranostics; 2018; 8(15):4050-4061. PubMed ID: 30128035
[TBL] [Abstract][Full Text] [Related]
11. Isocitrate dehydrogenase 2 contributes to radiation resistance of oesophageal squamous cell carcinoma via regulating mitochondrial function and ROS/pAKT signalling.
Chen X; Zhuo S; Xu W; Chen X; Huang D; Sun X; Cheng Y
Br J Cancer; 2020 Jul; 123(1):126-136. PubMed ID: 32367071
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic potential of the mitochondria-targeted antioxidant MitoQ in mitochondrial-ROS induced sensorineural hearing loss caused by Idh2 deficiency.
Kim YR; Baek JI; Kim SH; Kim MA; Lee B; Ryu N; Kim KH; Choi DG; Kim HM; Murphy MP; Macpherson G; Choo YS; Bok J; Lee KY; Park JW; Kim UK
Redox Biol; 2019 Jan; 20():544-555. PubMed ID: 30508699
[TBL] [Abstract][Full Text] [Related]
13. Mubritinib enhanced the inhibiting function of cisplatin in lung cancer by interfering with mitochondrial function.
Dong J; Zhu D; Chen M; Wang T; Gao Y; Liu W
Thorac Cancer; 2022 May; 13(10):1513-1524. PubMed ID: 35429141
[TBL] [Abstract][Full Text] [Related]
14. IDH2 knockdown sensitizes tumor cells to emodin cytotoxicity in vitro and in vivo.
Ku HJ; Kwon OS; Kang BS; Lee DS; Lee HS; Park JW
Free Radic Res; 2016 Oct; 50(10):1089-1097. PubMed ID: 27087448
[TBL] [Abstract][Full Text] [Related]
15. Reactive oxygen species-mediated senescence is accelerated by inhibiting Cdk2 in Idh2-deficient conditions.
Chae U; Park JW; Lee SR; Lee HJ; Lee HS; Lee DS
Aging (Albany NY); 2019 Sep; 11(17):7242-7256. PubMed ID: 31503005
[TBL] [Abstract][Full Text] [Related]
16. Activation of mitochondrial oxidation by PDK2 inhibition reverses cisplatin resistance in head and neck cancer.
Roh JL; Park JY; Kim EH; Jang HJ; Kwon M
Cancer Lett; 2016 Feb; 371(1):20-9. PubMed ID: 26607904
[TBL] [Abstract][Full Text] [Related]
17. IDH2 reprograms mitochondrial dynamics in cancer through a HIF-1α
Wang Y; Agarwal E; Bertolini I; Ghosh JC; Seo JH; Altieri DC
FASEB J; 2019 Dec; 33(12):13398-13411. PubMed ID: 31530011
[TBL] [Abstract][Full Text] [Related]
18. Isocitrate dehydrogenase 2 deficiency induces endothelial inflammation via p66sh-mediated mitochondrial oxidative stress.
Choi SJ; Piao S; Nagar H; Jung SB; Kim S; Lee I; Kim SM; Song HJ; Shin N; Kim DW; Irani K; Jeon BH; Park JW; Kim CS
Biochem Biophys Res Commun; 2018 Sep; 503(3):1805-1811. PubMed ID: 30072100
[TBL] [Abstract][Full Text] [Related]
19. Promotion of p53 expression and reactive oxidative stress production is involved in zerumbone-induced cisplatin sensitization of non-small cell lung cancer cells.
Hu Z; Zeng Q; Zhang B; Liu H; Wang W
Biochimie; 2014 Dec; 107 Pt B():257-62. PubMed ID: 25220870
[TBL] [Abstract][Full Text] [Related]
20. Curcuminoid WZ26, a TrxR1 inhibitor, effectively inhibits colon cancer cell growth and enhances cisplatin-induced cell death through the induction of ROS.
Zhang T; Zheng P; Shen X; Shao R; Wang B; Shen H; Zhang J; Xia Y; Zou P
Free Radic Biol Med; 2019 Sep; 141():93-102. PubMed ID: 31176737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
